From: Hybrid ileal pouch with concomitant anti-refluxing and refluxing ureteroileal anastomosis
 | Group A (N = 17) | Group B (N = 8) | Total (N = 25) | p |
---|---|---|---|---|
Age (years) | 63.4 ± 7.8 [59.0; 67.0] | 60.0 ± 12.0 [50.5; 69.0] | 62.3 ± 9.3 [57.5; 67.0] | 0.410 |
Male gender | 15 (88.2%) | 7 (87.5%) | 22 (88.0%) | 1.000 |
Height | 165.0 ± 7.9 [161.0; 170.8] | 165.5 ± 4.9 [162.7; 169.6] | 165.2 ± 7.0 [160.1; 169.7] | 0.887 |
Weight | 66.6 ± 8.7 [60.2; 75.3] | 64.7 ± 12.8 [56.8; 76.8] | 66.0 ± 9.9 [60.2; 76.0] | 0.665 |
Body mass index (kg/m2) | 24.5 ± 3.5 [21.6; 26.4] | 22.8 ± 3.5 [20.5; 26.4] | 24.0 ± 3.5 [21.3; 26.4] | 0.293 |
Diabetes mellitus | 3 (17.6%) | 2 (25.0%) | 5 (20.0%) | 1.000 |
Hypertension | 6 (35.3%) | 2 (25.0%) | 8 (32.0%) | 0.956 |
Clinical T stage | Â | Â | Â | 0.571 |
 ≤ T2 | 7 (41.2%) | 5 (62.5%) | 12 (48.0%) |  |
 ≥ T3 | 10 (58.8%) | 3 (37.5%) | 13 (52.0%) |  |
Clinical lymph node positive | 3 (17.6%) | 1 (12.5%) | 4 (16.0%) | 1.000 |
Preoperative grade | Â | Â | Â | 0.544 |
G2 | 3 (20.0%) | 0 (0.0%) | 3 (12.0%) | Â |
G3 | 12 (80.0%) | 7 (100.0%) | 19 (76.0%) | Â |
Neoadjuvant chemotherapy | 1 (5.9%) | 2 (25.0%) | 3 (12.0%) | 0.476 |